title: Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience.
abstract: BACKGROUND
  Adenoid cystic carcinoma of the sinonasal tract is a rare cancer that accounts for 10% of all malignancies at this site. The objective of the current study was to evaluate prognostic factors, treatment outcomes, recurrence patterns, and survival rates for sinonasal adenoid cystic carcinoma.
  
  
  METHODS
  A retrospective chart review was performed at an academic tertiary referral center. Between 1990 and 2004, 105 patients were evaluated for adenoid cystic carcinoma of the sinonasal tract at a single institution. Demographics, presentation, anatomic site, Tumor, Lymph Node, Metastasis (TNM) classification, pathology, treatment, recurrences, and survival were evaluated.
  
  
  RESULTS
  One hundred five patients with adenoid cystic carcinoma were evaluated, including 58 women and 47 men. Their median age was 50 years, and the mean follow-up was 47 months. The maxillary sinus (47%) and the nasal cavity (30%) were the most common primary tumor sites. The majority of patients presented with T3/T4 (76.7%), N0 (98%), M0 (97%) disease. Eighty-four percent of patients underwent surgery and received postoperative radiation as treatment for their primary disease. The local recurrence rate was 30%, and the distant metastases rate was 38%. The 5-year overall survival and disease specific survival rates were 62.9% and 70.9%, respectively.
  
  
  CONCLUSIONS
  Adenoid cystic carcinoma of the paranasal sinuses is a rare disease, and the ideal treatment paradigm has yet to be defined. The current data suggested that surgical resection with postoperative radiation therapy offers durable local control and compares favorably with historic data. Although local recurrences develop in a significant percentage of patients, survival from this disease exceeds that of other sinonasal malignancies.
authors.affiliation: Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4095, USA.
authors.forename: Allison D
authors.initials: AD
authors.lastname: Lupinetti
authors.forename: Dianna B
authors.initials: DB
authors.lastname: Roberts
authors.forename: Michelle D
authors.initials: MD
authors.lastname: Williams
authors.forename: Michael E
authors.initials: ME
authors.lastname: Kupferman
authors.forename: David I
authors.initials: DI
authors.lastname: Rosenthal
authors.forename: Franco
authors.initials: F
authors.lastname: Demonte
authors.forename: Adel
authors.initials: A
authors.lastname: El-Naggar
authors.forename: Randal S
authors.initials: RS
authors.lastname: Weber
authors.forename: Ehab Y
authors.initials: EY
authors.lastname: Hanna
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003528:Carcinoma, Adenoid Cystic / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms; D010255:Paranasal Sinus Neoplasms / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D016019:Survival Analysis